ClinicalTrials.gg
TerminatedNCT04590664Updated Oct 28, 2026Results posted

Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

A Phase 1/2 interventional study of Verteporfin in Glioblastoma and Recurrent Glioblastoma, sponsored by Emory University. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Emory University · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
PI Decision
Updated Oct 28, 2026Now TerminatedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Glioblastoma by Emory University — none open to participants now, 1 under way, none of them phase 3. Glioblastoma · Emory University.

Enrollment
7th of 11
9 · median 12
Started
2021
with 1 other
Phase 1/2
Only one
of the 12
Registered
8th of 12
by date

Among the 12 studies in Glioblastoma by Emory University, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2021, is the only one in phase 1/2, and was the 8th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

None of the 12 studies in Glioblastoma by Emory University is open now. The open studies under Glioblastoma, anywhere →

Where they have run

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Glioblastoma by Emory University as a file.
02

Study summary

This phase I/II trial studies the side effects and best dose of Visudyne (liposomal verteporfin) and to see how well it works in treating patients with high grade EGFR-mutated glioblastoma that has come back (recurrent).

Visudyne is FDA approved in combination with light to treat eye diseases. In this study we use Visudyne by itself like chemotherapy to kill tumor cells which may be sensitive to verteporfin.

Read the detailed description

PRIMARY OBJECTIVES:

I. To evaluate the safety and tolerability of successively higher doses of verteporfin (Visudyne [liposomal verteporfin]) and determine the maximum tolerated dose (MTD) in study participants with recurrent EGFR positive (+) glioblastoma (GBM). (Phase I) II. To evaluate the anti-tumor activity of Visudyne by assessing progression-free survival (PFS) and overall survival (OS). (Phase II) III. To describe the response rate of EGFR+ GBM in study participants treated with Visudyne. (Phase II)

SECONDARY OBJECTIVES:

I. To evaluate the anti-tumor activity of Visudyne by assessing progression-free survival (PFS) and overall survival (OS). (Phase I) II. To describe the response rate of EGFR+ GBM in study participants treated with Visudyne. (Phase I) III. To describe pharmacokinetics of Visudyne administered on a weekly schedule. (Phase I) IV. To evaluate the safety and tolerability of successively higher doses of Visudyne in study participants with recurrent EGFR+ GBM. (Phase II)

OUTLINE: This is a dose-escalation study.

Patients receive verteporfin intravenously (IV) over 83 minutes weekly for 6 weeks in cycle 1, then weekly for 5 weeks in subsequent cycles. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days and then every 12 weeks.

03

Conditions studied

  • Glioblastoma
  • Recurrent Glioblastoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Persons with recurrent or progressive grade 4 glioma (glioblastoma) are eligible for this study. Participants should have received standard therapy including radiation and temozolomide
  • Eligible participants have tumors that show mutant or amplified EGFR. This determination can be made using standard of care mutation analysis panels (e.g. Snapshot). It is often assessed at diagnosis as part of standard of care
  • Eligible participants must have evidence on magnetic resonance imaging (MRI) of progression. This may be as new or increased enhancement, or growth / increase in nonenhancing abnormality. Care should be taken to distinguish those with true progression from those with radiation related changes. Persons with changes in enhancement possibly due in part or in whole to late radiation effect should receive bevacizumab as standard of care, and defer study participation
  • Participants may be receiving bevacizumab, and show progression while on bevacizumab. These participants may continue bevacizumab while on study. Persons not on bevacizumab but who would benefit from the anti-edema effect of bevacizumab should not enroll on this study but should proceed with bevacizumab alone, and defer enrollment until such time as they progress
  • Visudyne is a vesicant. Participants will likely have poor veins, and will require repeated intravenous treatments. Participants must be willing to have placed a central venous access, such as a portacath
  • (ECOG) performance status (PS) 0-3. Participants who are ECOG 2 or 3 should ideally have been in that situation for some time, and not be in the midst of rapid clinical decline
  • Medical comorbidities (excepting neurological) must be grade 2 or less if graded as toxicity
  • Eligible participants may have grade 3 neurologic comorbidities (for example aphasia, ataxia) arising as a consequence of brain pathology
  • Participants should be reasonably expected to be able to complete 6 weeks (1 cycle) of treatment on study before death or worsening of PS to 4 or 5
  • Other anti-cancer medical treatments. Treatments in this category include chemotherapy and non-bevacizumab therapies. 7 days must have elapsed since discontinuation of prior chemotherapeutic treatments for glioma and study treatment. Participants may have had any number of prior treatments
  • All participants on this study must have had prior radiation to the brain. Radiation must have been completed 90 days prior to first study treatment
  • 21 days must have elapsed since prior major surgery
  • Participants already using a Novo-tumor treating fields therapy (TTF) (Optune) device and who wish to continue may do so
  • All participants must sign a written
  • The effects of study drugs used in this study on the developing human fetus are unknown. For this reason, female of (FCBP) must have a negative serum or urine pregnancy test prior to starting therapy
  • FCBP and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and 8 weeks after. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation. A female of childbearing potential (FCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months

Exclusion criteria

Exclusion Criteria:

  • Persons who are deemed to have progression on clinical grounds only (new symptoms, declining PS) are ineligible. In the absence of MRI change one cannot be confident that clinical deterioration is a direct result of tumor progression, and could be due to intercurrent illness
  • Persons with edema which might be due to late radiation effect, not true progression, should receive bevacizumab as standard of care, and defer study participation. If (short-term) followup imaging shows reduction of edema and also progression of tumor, these persons are eligible (and should continue bevacizumab)
  • Pregnant or breast-feeding women will not be entered on this study
  • Participants may not have any baseline comorbidities or laboratory abnormalities which would be of grade 3 or worse if graded as toxicities by (CTCAE) (excepting alopecia). An exception is made for neurologic comorbidities (e.g. ataxia, aphasia) arising as a consequence of the brain tumor; symptoms severe enough to warrant medical treatment as is offered on this study are by definition grade III
  • Persons who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are ineligible
  • Illness or any other circumstances (as defined by the investigator), which would preclude safe performance of study procedures or compromise the ability of the patient to consent to study
  • Persons with hereditary porphyria are ineligible
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Treatment (verteporfin)

    Patients receive verteporfin IV over 83 minutes weekly for 6 weeks in cycle 1, then weekly for 5 weeks in subsequent cycles. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

    Drug: Verteporfin

Interventions

  • Given IV

    Also known as: Benzoporphyrin Derivative Monoacid Ring A, BPD-MA, Visudyne

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (Phase I)

    Will be graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. For each adverse event, information to be collected includes event description, time of onset, clinician assessment of severity, relationship to study product (assessed only by those with the training and authority to make a diagnosis), and time of resolution/stabilization of the event.\[

    Time frame: Safety follow-up is 30 days after the last drug administered (at Day 36 +/- 1 day) *see protocol[

07

Results

Posted Oct 28, 2026

Participant flow

11 participants recruited; 9 went on to receive protocol treatment.

Participant flow — Overall Study
MilestoneDose Level 1Dose Level 2Dose Level 3Dose Level 4
Started3231
Completed3231
Not completed0000

Outcome measures

PrimaryIncidence of Adverse Events (Phase I)

Will be graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. For each adverse event, information to be collected includes event description, time of onset, clinician assessment of severity, relationship to study product (assessed only by those with the training and authority to make a diagnosis), and time of resolution/stabilization of the event.\[

Time frame:
Safety follow-up is 30 days after the last drug administered (at Day 36 +/- 1 day) *see protocol[
Reported as:
Count of participants · Participants
Incidence of Adverse Events (Phase I)
ParticipantsDose Level 1Dose Level 2Dose Level 3Dose Level 4
Any2131
Blood and lymphatic system disorders0010
Ear and labyrinth disorders0010
Gastrointestinal disorders0011
General disorders and administration site conditions1111
Infections and infestations0010
Injury, poisoning and procedural complications0010
Investigations1000
Musculoskeletal and connective tissue disorders1000
Nervous system disorders2110
Renal and urinary disorders0011
Skin and subcutaneous tissue disorders1010

Adverse events

Collected over 4 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level 13/3 (100%)0/3 (0%)2/3 (66.7%)
Dose Level 22/2 (100%)0/2 (0%)1/2 (50%)
Dose Level 33/3 (100%)1/3 (33.3%)3/3 (100%)
Dose Level 41/1 (100%)0/1 (0%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventDose Level 1Dose Level 2Dose Level 3Dose Level 4
SeizureNervous system disorders0/30/21/30/1
Most frequent other events
Showing 10 of 26
Most frequent other events
EventDose Level 1Dose Level 2Dose Level 3Dose Level 4
General disorders and administration site conditions - Other, specifyGeneral disorders1/30/22/31/1
Gastrointestinal disorders - Other, specifyGastrointestinal disorders0/30/20/31/1
Urinary frequencyRenal and urinary disorders0/30/20/31/1
Urine discolorationRenal and urinary disorders0/30/20/31/1
FatigueGeneral disorders0/31/21/30/1
HeadacheNervous system disorders0/31/20/30/1
SeizureNervous system disorders0/31/21/30/1
FallInjury, poisoning and procedural complications1/30/20/30/1
Creatinine increasedInvestigations1/30/20/30/1
Muscle weakness lower limbMusculoskeletal and connective tissue disorders1/30/20/30/1

Baseline characteristics

Age, Continuous
Age, Continuous(years)Dose Level 1Dose Level 2Dose Level 3Dose Level 4Total
Mean59.33 ± 9.4568.5 ± 9.1955 ± 14.865 ± NA60.6 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level 1Dose Level 2Dose Level 3Dose Level 4Total
Female20114
Male12205
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Level 1Dose Level 2Dose Level 3Dose Level 4Total
American Indian or Alaska Native00000
Asian00101
Native Hawaiian or Other Pacific Islander00000
Black or African American01001
White31217
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Dose Level 1Dose Level 2Dose Level 3Dose Level 4Total
United States32311
08

Study locations

1 site
  • Emory University Hospital/Winship Cancer Institute
    Atlanta, Georgia 30322, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2021 to primary completion in Feb 2025, 48 months.

Results were first posted in Oct 2026, 1 year 8 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Aug 2025 → Feb 2025 and completion Aug 2025 → Feb 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2020
First posted
Oct 19, 2020
StartActual
Jan 15, 2021
Primary completionActual
Feb 13, 2025was Aug 2025
CompletionActual
Feb 13, 2025was Aug 2025
Results first posted
Oct 28, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated PI Decision
changed Oct 28, 2026
Results
Results posted
posted Oct 28, 2026
Primary completion
Aug 15, 2025→Feb 13, 2025 (actual)
Oct 28, 2026
Study completion
Aug 15, 2025→Feb 13, 2025 (actual)
Oct 28, 2026
Enrollment
24 (estimated)→9 (actual)
Oct 28, 2026
Primary outcomes
1 edited, 3 removed
What changed in the outcomes
  • EditedIncidence of adverse eventsAdverse Events (Phase I)Time frame: From study enrollment until 100 days after the last day of study participation → Safety follow-up is 30 days after the last drug administered (at Day 36 +/- 1 day) *see protocol[
  • RemovedProgression free survival (PFS) (Phase II)Time frame: At 6 weeks
  • RemovedResponse rate (RR) (Phase II)Time frame: From study enrollment until 2 years
  • RemovedOverall survival (Phase II)Time frame: Time from study enrollment to death or last follow-up, assessed up to 2 years
Oct 28, 2026
Secondary outcomes
5 removed
What changed in the outcomes
  • RemovedPFS (Phase I)Time frame: From study enrollment to 2 years
  • RemovedRR (Phase I)Time frame: From study enrollment to 2 years
  • RemovedOverall survival (Phase I)Time frame: Time from study enrollment to death or last follow-up, assessed up to 2 years
  • RemovedVisudyne blood levels (Phase I)Time frame: At timepoints following administration
  • RemovedIncidence of adverse events (Phase II)Time frame: From study enrollment to 2 years
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Terminated
    Why stopped PI Decision
    Results posted
    Primary completion Aug 15, 2025→Feb 13, 2025 (now actual)
    Study completion Aug 15, 2025→Feb 13, 2025 (now actual)
    Enrollment 24 (estimated)→9 (actual)
    Primary outcomes 1 edited, 3 removed
    What changed in the outcomes
    • EditedIncidence of adverse eventsAdverse Events (Phase I)Time frame: From study enrollment until 100 days after the last day of study participation → Safety follow-up is 30 days after the last drug administered (at Day 36 +/- 1 day) *see protocol[
    • RemovedProgression free survival (PFS) (Phase II)Time frame: At 6 weeks
    • RemovedResponse rate (RR) (Phase II)Time frame: From study enrollment until 2 years
    • RemovedOverall survival (Phase II)Time frame: Time from study enrollment to death or last follow-up, assessed up to 2 years
    Secondary outcomes 5 removed
    What changed in the outcomes
    • RemovedPFS (Phase I)Time frame: From study enrollment to 2 years
    • RemovedRR (Phase I)Time frame: From study enrollment to 2 years
    • RemovedOverall survival (Phase I)Time frame: Time from study enrollment to death or last follow-up, assessed up to 2 years
    • RemovedVisudyne blood levels (Phase I)Time frame: At timepoints following administration
    • RemovedIncidence of adverse events (Phase II)Time frame: From study enrollment to 2 years
    + 7 other changes: index terms, identifiers, verification date, registry dates, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04590664
Lead sponsor
Emory University
Responsible party
William Read (Principal Investigator, Emory University) — Principal investigator
First posted
Oct 19, 2020
Start date
Jan 15, 2021
Primary completion
Feb 13, 2025
Completion
Feb 13, 2025
Results posted
Oct 28, 2026
Last update
Oct 28, 2026

Study contacts

William L Read, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Verteporfin

Start the discussion